Evidence map›Paper›PMID 40801742›Full record

ReviewNanomaterials (Basel, Switzerland)2025

Current Research Trends and Hotspots in Radiotherapy Combined with Nanomaterials for Cancer Treatment: A Bibliometric and Visualization Analysis.

Muyasha Abulimiti, Shiqin Dai, Ebara Mitsuhiro, Yu Sugawara, Yinuo Li, Hideyuki Sakurai, Yoshitaka Matsumoto

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muyasha AbulimitiDepartment of Radiation Oncology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba 305-8575, Japan.ORCID 0009-0006-3707-5366
Shiqin DaiResearch Center for Functional Materials, National Institute for Materials Science (NIMS), Tsukuba 305-0044, Japan.ORCID 0009-0000-3070-8358
Ebara MitsuhiroResearch Center for Functional Materials, National Institute for Materials Science (NIMS), Tsukuba 305-0044, Japan.ORCID 0000-0002-7906-0350
Yu SugawaraDepartment of Radiation Oncology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba 305-8575, Japan.
Yinuo LiProton Medical Research Center, University of Tsukuba Hospital, Tsukuba 305-8576, Japan.ORCID 0000-0002-0423-2541
Hideyuki SakuraiProton Medical Research Center, University of Tsukuba Hospital, Tsukuba 305-8576, Japan.
Yoshitaka MatsumotoProton Medical Research Center, University of Tsukuba Hospital, Tsukuba 305-8576, Japan.ORCID 0000-0002-2074-3042

Funding

JST SPRING JPMJSP2124
6 · The paper itself

Abstract

This study investigated the evolving trends, current research hotspots, and future directions of radiotherapy combined with nanobiomaterials through a bibliometric analysis. Publications related to nanobiomaterials used in radiotherapy between 2004 and 2024 were retrieved from the Web of Science Core Collection database and analyzed using VOSviewer, R, and CiteSpace. China emerged as the leading contributor, accounting for 1051 publications (50.41%), followed by the USA. Liu Zhuang is the most productive author in this field. American Chemical Society (ACS) Nano published the most influential articles and accumulated the highest number of citations. Advanced Targeted Therapies in Cancer: Drug Nanocarriers, the Future of Chemotherapy was the most cited, with 1255 citations. Citation bursts have revealed emerging research trends in targeted delivery, cellular studies, co-delivery strategies, immunogenic cell death, polymeric nanoparticles, tumor research, and drug delivery systems, indicating potential avenues for future research. Over the past two decades, nanomaterials for radiotherapy have gained substantial attention. Key areas of focus include enhancing the efficacy of radiotherapy, achieving targeted drug delivery, minimizing adverse effects, and integrating nanomaterials with other therapeutic modalities. Future investigations are expected to improve the precision of radiotherapy, augment radiation effects, and optimize the tumor microenvironment.

Indexed as

cancerdrug deliverynanobiomaterialsnanomaterialsradiotherapy

Identifiers

PMID40801742
PMCPMC12348538

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.